Figure 5. Wnt/β-catenin signaling involved in TYRO3-facilitated gastric cancer (GC) cell epithelial-mesenchymal transition growth, migration, and invasion. (A) Western blot analysis of the indicated expression levels (β-catenin, c-myc, cyclinD1, survivin, E-cadherin, Slug, and N-cadherin) in modified GC cells treated with the Wnt/β-catenin signaling inhibitor, XAV939 (15 μM). Determination of the proliferative capability of modified GC cells with XAV939 (15 μM) treatment using the CCK-8 assay (B) and colony formation assay (C). (D) Determination of the migratory and invasive capabilities of modified GC cells with XAV939 (15 μM) treatment, using the Transwell assay. Glyceraldehyde 3-phosphate dehydrogenase was used as a loading control. *P < 0.05.